Expansion Opportunities Novum is a mid-sized CRO with a long history in early phase and late phase clinical trials, serving global pharmaceutical clients. Their presence in multiple U.S. sites (Texas, Nevada, North Dakota) and a Pittsburgh-based late-phase division suggests opportunities to pitch integrated turnkey programs spanning Phase I–IV, particularly for sponsors seeking geographically diverse trial capabilities.

Strategic Partnerships Recent leadership changes and mergers (acquisition by Lambda Therapeutic Research in 2019 and a President/COO appointment in 2025) indicate a growth-focused strategy. This opens doors for co-development or preferred partner arrangements, especially with mid- to large-cap sponsors looking for reliable CROs with a credible track record and growth trajectory.

Pharmacology Strength Novum emphasizes early-phase research, including First-in-Human, SAD/MAD, BA/BE, cardiac safety, and specialized populations. Sales opportunities exist in sponsors needing robust early pharmacology services with strong PK-PD, drug-device interplay, and specialized testing, bundled with broader clinical trial management.

Clinical Trial Footprint With facilities in Houston, Las Vegas, Fargo, and Pittsburgh and a focus on diverse therapeutic areas through late-phase management, there is potential to win trials requiring site access in these regions, especially for programs needing patient recruitment in dermatology, GI, orthopedics, and women's health.

Industry Reputation Having earned CRO Leadership Awards in 2019 and maintaining a longstanding presence in the market, Novum can leverage its credibility to target risk-averse sponsors seeking quality, integrity, and reliability in key trial phases, as well as opportunities to expand into adjacent services such as medical affairs and project management enhancements.